Chemours Company (The) ($CC) Stock Forecast: Down 5.6% Today

What is Chemours Company (The)?

A chemical company, The Chemours Company (CC), is currently facing volatile market movements. Despite a recent intraday surge and positive short-term performance, the company is confronting long-term financial challenges.

Why is Chemours Company (The) going down?

CC stock is down 5.6% on Mar 19, 2026 14:01

• Today's significant bearish movement in CC's stock might be related to investors having a negative reaction towards the company's cautious capital allocation approach. This was highlighted by a debt refinance with higher coupon rates, an increase in CEO pay, and a dividend cut.
• Concerns have been raised among investors due to long-term challenges like a high debt-to-equity ratio and negative return on equity, which could have led to the stock sell-off.
• Although there has been positive short-term performance and an earnings beat as of late, investor sentiment may be impacted by ongoing PFAS liabilities and market risks, ultimately contributing to today's bearish market movement.

CC Price Chart

CC Technical Analysis

CC News

Chemours Co. Hits Day High with Strong 7.65% Intraday Surge

The Chemours Co. experienced a significant 7.65% intraday surge, reaching a high of USD 20.08, vastly outperforming the S&P 500 recently. Despite strong short-term stock performance, including a 30.07% gain over the past year, the company faces long-term challenges such as a high debt-to-equity ratio of 13.88 and a negative return on equity of -4.80%, indicating ongoing financial concerns. Its stock has declined over a three and five-year period.

https://www.marketsmojo.com/news/stocks-in-action/chemours-co-hits-day-high-with-strong-765-intraday-surge-3899180

Penn Capital Management Company LLC Buys Shares of 651,151 The Chemours Company $CC

Penn Capital Management Company LLC acquired 651,151 shares of The Chemours Company (NYSE:CC) in the third quarter, valued at approximately $10.33 million, representing 0.43% of the company's stock. Other institutional investors also adjusted their holdings, with institutional ownership reaching 76.26%. Analysts maintain a consensus "Hold" rating with a target price of $18.40, while Chemours recently reported better-than-expected earnings and pays a quarterly dividend.

https://www.marketbeat.com/instant-alerts/filing-penn-capital-management-company-llc-buys-shares-of-651151-the-chemours-company-cc-2026-03-18/

The Chemours Co (CC) Stock Price Up 10.54% on Mar 17

Shares of The Chemours Co (CC) surged 10.54% in mid-day trading on March 17, closing at $19.50. This places the stock 10.76% below its 52-week high and significantly above its 52-week low. Wall Street analysts maintain a "Hold" status with an average price target of $19.63, while GuruFocus estimates a one-year fair value of $21.49, suggesting a potential upside.

https://www.gurufocus.com/news/8719620/the-chemours-co-cc-stock-price-up-1054-on-mar-17

Cinctive Capital Management LP Cuts Stock Position in The Chemours Company $CC

Cinctive Capital Management LP significantly reduced its stake in The Chemours Company ($CC) by 77.6% in Q3, selling 258,396 shares. Despite this, other major institutional investors like State Street, Ameriprise, Geode Capital Management, and UBS Group AG increased their positions, indicating strong institutional ownership at 76.26%. Chemours beat Q3 earnings expectations, reported $1.33 billion in revenue, and pays a quarterly dividend, maintaining a "Hold" consensus among analysts with an average price target of $18.40.

https://www.marketbeat.com/instant-alerts/filing-cinctive-capital-management-lp-cuts-stock-position-in-the-chemours-company-cc-2026-03-17/

How Investors Are Reacting To Chemours (CC) Debt Refinance And CEO Pay Hike

Chemours (CC) recently refinanced existing debt by issuing US$700 million in 7.875% senior unsecured notes due 2034, extending maturities but at a higher coupon rate. This move, combined with a 31.5% increase in CEO Denise Dignam's compensation and a dividend cut, signals a cautious capital allocation strategy amidst ongoing PFAS liabilities and market risks. While analysts project significant revenue and earnings growth by 2028, these projections remain sensitive to potential PFAS-related cash outflows.

https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/how-investors-are-reacting-to-chemours-cc-debt-refinance-and

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.3% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.5% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.1% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Up 6.0% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 5.2% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 8.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.9% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.6% Today

10x Genomics, Inc. ($TXG) Stock Forecast: Up 5.1% Today

Schlumberger N.V. ($SLB) Stock Forecast: Up 5.1% Today

Chemours Company (The) Price History

23.01.2026 - CC Stock was up 5.2%

• The stock of Chemours (CC) experienced a strong bullish movement today.
• Positive adjustments to price targets and ratings likely boosted investor confidence in the company's future prospects.
• Despite facing challenges such as disappointing Q4 earnings and ongoing litigation, Chemours' focus on implementing pricing actions and divesting assets to strengthen its financial position seems to have resonated positively with investors.
• The company's projected consolidated net sales growth for 2026 and improved adjusted EBITDA and free cash flow outlook might have contributed to the bullish sentiment surrounding the stock today.

04.02.2026 - CC Stock was up 5.1%

• The upward movement in CC's stock may be attributed to the favorable quarterly EPS results and outperforming expectations despite a decrease in revenue compared to the previous year.
• Actions like equity grants and share withholdings for tax obligations by Chemours executives may have boosted investor confidence in the company's future outlook.
• Following a stock price decline after the financial results, ongoing investigations by a legal firm might have initially caused market uncertainty, but positive performance indicators helped restore investor faith and drive the bullish movement.
• Despite Quantbot Technologies LP reducing its stake in Chemours, the company's dividend announcement and overall financial health likely reassured investors, contributing to the upward trajectory.

03.02.2026 - CC Stock was down 7.9%

• Stake reductions by Quantbot Technologies LP and Vanguard Group Inc. indicate a lack of confidence in the company.
• Negative sentiment is heightened by an ongoing investigation into the company following a stock price drop linked to one-time inventory charges and market challenges.
• Despite surpassing quarterly EPS estimates and achieving a positive return on equity, a year-over-year revenue decline may have contributed to the stock's bearish performance.
• The bullish outlook from FelixQE's Substack, emphasizing the company's undervaluation and growth potential amidst PFAS litigation, stands in contrast to prevailing market sentiment, indicating a divergence in investor perspectives.

24.01.2026 - CC Stock was up 5.0%

• Chemours Co reported a net loss mainly attributed to litigation-related charges and increased costs, impacting its financial performance negatively in its annual Form 10-K report.
• Despite the loss, Chemours is working on strengthening its ties with the semiconductor industry, increasing adoption of its Opteon refrigerants, and streamlining its portfolio through asset sales for debt reduction.
• The company is encountering operational challenges and legal issues, including a lawsuit regarding PFAS contamination. This situation might have influenced the negative market sentiment, although there is anticipated support from its Opteon product line as Jefferies raised its stock price target.

19.02.2026 - CC Stock was down 5.6%

• Today's significant bearish movement in CC's stock might be related to investors having a negative reaction towards the company's cautious capital allocation approach. This was highlighted by a debt refinance with higher coupon rates, an increase in CEO pay, and a dividend cut.
• Concerns have been raised among investors due to long-term challenges like a high debt-to-equity ratio and negative return on equity, which could have led to the stock sell-off.
• Although there has been positive short-term performance and an earnings beat as of late, investor sentiment may be impacted by ongoing PFAS liabilities and market risks, ultimately contributing to today's bearish market movement.

05.02.2026 - CC Stock was down 5.4%

• Analysts have raised their price targets for Chemours, showing optimism and positive expectations for the stock.
• An investigation into potential claims against Chemours following a stock price decrease due to a one-time inventory charge may have impacted the bearish movement.
• Reports of an executive receiving restricted stock units (RSUs) and shares being held for tax purposes might have also influenced investor sentiment.
• The contrasting information of price target increases and investigations into financial disclosures likely caused uncertainty and contributed to the downward trend in Chemours' market performance today.

27.01.2026 - CC Stock was up 5.5%

• Chemours (CC) experienced a bullish trend today due to investor focus on the company's new AI cooling partnership and analyst updates.
• The successful private offering of $700 million in senior notes due 2034 also contributed to the positive market movement.
• Despite concerns raised by a law firm regarding potential securities fraud and market headwinds, the company's undervaluation according to discounted cash flow models and price-to-sales ratios has helped reassure investors.
• The company's valuation and recent financial results have inspired volatility, but the overall market sentiment remains optimistic about Chemours' future prospects.

26.01.2026 - CC Stock was down 5.4%

• The bearish movement in Chemours (CC) stock today could be attributed to profit-taking by investors after a period of undervaluation.
• The increase in price targets by financial institutions may have initially boosted confidence in the stock, but the market sentiment might have shifted due to concerns about the company's negative net margin and P/E ratio.
• The joint development agreement with 2CRSi for advanced cooling solutions could be a positive long-term catalyst for Chemours, but short-term market dynamics might have overshadowed this news.
• Overall, the bearish movement in CC's stock today seems to reflect a mix of valuation concerns, profit-taking, and short-term market sentiment, despite promising developments in its technology partnerships.

17.02.2026 - CC Stock was up 7.5%

• Reasons for the recent strong stock performance of Chemours include:
• Reduction of 77.6% in Cinctive Capital Management LP's stake, signaling a shift in positions.
• Successful completion of a $700 million private offering of senior unsecured notes due 2034, bolstering investor trust in the company's financial structure.
• Despite worries about PFAS liabilities and market risks, the company exceeded Q3 earnings expectations with $1.33 billion in revenue and maintained a quarterly dividend, painting a positive picture for investors.
• Discordant fair value assessments and differing opinions on the company's actual value may have led to stock price volatility, prompting today's upward movement as investors reevaluate their positions in light of the latest developments.

17.02.2026 - CC Stock was up 6.0%

• Chemours opted to refinance existing debt through the issuance of $700 million in senior unsecured notes due 2034. Despite a higher coupon rate, extended maturities, and a dividend cut, this move reflects a prudent capital allocation strategy amidst ongoing PFAS liabilities and market risks.
• The disparity in fair value signals for the stock adds to investor uncertainty. While a DCF model indicates an undervaluation at $49.99, a different valuation pegs it at $16.33, creating the need for thorough due diligence.
• Wolf Hill Capital Management LP's recent acquisition of a stake in Chemours, combined with positive Q3 earnings and a consensus "Hold" rating from analysts, has fueled market optimism. Investors seem confident in the company's potential for future growth.
• The successful completion of a private offering for $700 million in senior unsecured notes due 2034, aimed at optimizing the balance sheet by refinancing existing obligations and funding note redemptions, has further buoyed investor sentiment and propelled the stock's upward trajectory.

10.02.2026 - CC Stock was up 7.1%

• Factors contributing to CC's stock price surge include:
• A strong earnings per share (EPS) beat and the company's announcement of a quarterly dividend, potentially boosting investor confidence.
• Despite encountering obstacles like a one-time inventory charge and short-term market challenges, the stock demonstrated resilience and attracted new institutional investors.
• Positive technical indicators hinting at a bullish to mildly bullish trend for the stock likely heightened traders' optimism.
• Despite initial uncertainties surrounding an investigation, investors appear positive about CC's future prospects based on the stock's performance.

09.02.2026 - CC Stock was up 5.0%

• An inquiry triggered by a specific firm in response to the stock price drop may have rattled investors initially, yet subsequent market activity indicates a more positive investor sentiment.
• The increased institutional investments from Neo Ivy Capital Management and American Century Companies Inc. signal a growing belief in Chemours' long-term prospects, despite varied analyst evaluations and recent downward revisions in earnings forecasts.
• Chemours' adoption of Adobe Marketo Engage to enhance marketing outcomes demonstrates a commitment to expansion and customer interaction, potentially contributing to the recent positive market trends.
• While short-term hurdles may have affected Chemours' stock value, the company's strategic efforts and investor trust appear to be propelling the recent market upswing.